



## **Alkermes to Webcast Analyst and Investor Day**

June 12, 2007

CAMBRIDGE, Mass.--(BUSINESS WIRE)--June 12, 2007--Alkermes, Inc. (NASDAQ: ALKS) announced today that its Analyst and Investor Day presentations will be webcast live on the investor relations section of its website at [www.alkermes.com](http://www.alkermes.com).

Alkermes senior management will review the company's commercial products, operations capabilities, and advancing pipeline. The presentations will be delivered on Tuesday, June 19, 2007 beginning at approximately 8:30 a.m. ET and ending at 12:00 p.m. ET from the Sofitel Hotel, 45 West 44th Street, New York. This webcast will be archived for seven days. Audio of the event will also be accessible by telephone by dialing 1-866-277-1182 from the U.S. or Canada, or 1-617-597-5359 internationally. For further information, please contact Debra Koufos at (617) 583-6220.

Alkermes, Inc. is a biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease. Alkermes currently has two commercial products: RISPARDAL® CONSTA® ((risperidone) long-acting injection), the first and only long-acting atypical antipsychotic medication approved for use in schizophrenia, and marketed worldwide by Janssen-Cilag (Janssen), a wholly owned division of Johnson & Johnson; and VIVITROL® (naltrexone for extended-release injectable suspension) the first and only once-monthly injectable medication approved for the treatment of alcohol dependence and marketed in the U.S. primarily by Cephalon, Inc. Alkermes' pipeline includes extended-release injectable, pulmonary, and oral products for the treatment of prevalent, chronic diseases such as central nervous system disorders, addiction and diabetes. Alkermes' headquarters are in Cambridge, Massachusetts, and it operates research and manufacturing facilities in Massachusetts and Ohio.

CONTACT: Alkermes, Inc.  
Debra Koufos, 617-583-6220  
Associate, Corporate Communications

SOURCE: Alkermes, Inc.